A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
Saved in:
| Title: | A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. |
|---|---|
| Authors: | Golbourn B; John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Ho B; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Bondoc A; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Luck A; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Fan X; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Richardson E; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Marcellus R; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Prakesch M; Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Halbert M; John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Agrawal N; John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA., Smith C; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada., Huang A; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Rutka JT; Cell Biology Research Program, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada. |
| Source: | Neuro-oncology [Neuro Oncol] 2024 Oct 03; Vol. 26 (10), pp. 1895-1911. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noae120 |
